Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Arizona State University and Silicon Kingdom Holdings Announce Agreement to Deploy World’s First Commercially Viable Passive Carbon Capture Technology

Published

on

Reading Time: 4 minutes

Powerful Mechanical Trees Can Remove CO2 From
the Air to Combat Global Warming at Scale

TEMPE, Ariz. & DUBLIN–(BUSINESS WIRE)–Arizona State University (ASU) and Silicon Kingdom Holdings (SKH)
announce an agreement to deploy carbon capture technology developed by
Professor Klaus Lackner, director of ASU’s Center for Negative Carbon
Emissions (CNCE).

The proprietary technology acts like a tree that is thousands of times
more efficient at removing CO2 from the air. The “mechanical
trees” allow the captured gas to be sequestered or sold for re-use in a
variety of applications, such as synthetic fuels, enhanced oil recovery
or in food, beverage and agriculture industries.

Unlike other carbon capture technologies, SKH’s technology can remove CO2
from the atmosphere without the need to draw air through the system
mechanically, using energy intensive devices. Instead, the technology
uses the wind to blow air through the system. This makes it a passive,
relatively low-cost and scalable solution that is commercially viable.
If deployed at scale, the technology could lead to significant
reductions in the levels of CO2 in Earth’s atmosphere,
helping to combat global warming.

CO₂ is an odorless, colorless gas that is a byproduct of burning fossil
fuels and other natural processes. Humans release more than 36 billion
metric tons of CO2 into the atmosphere annually,
significantly changing Earth’s natural carbon cycle. The excess carbon
traps heat and causes global warming.

The situation has gotten to the point where we need to stop talking
about it and start doing something about it,” said Lackner, an ASU
engineering professor in the School of Sustainable Engineering and the
Built Environment. “Carbon dioxide is a waste product we produce every
time we drive our cars or turn on the lights in our homes. Our device
can recycle it, bringing it out of the atmosphere and either bury it or
use it as an industrial gas,” added Lackner, who will serve as the chief
scientific adviser to SKH.

The “mechanical tree” is a novel geometry which is agnostic to the wind
direction. Each one contains a stack of sorbent filled disks. When the
tree-like column is fully extended and the disks spread apart, air flow
makes contact with the surfaces and the CO₂ gets bound up. During
regeneration, the disks are lowered inside the bottom container. Inside
the chamber, the CO2 is released from the sorbent. The
released gas is then collected, purified, processed and put to other
uses, while the disks are redeployed to capture more CO2.

Until now, technologies being developed to capture CO2 from
the air have been constrained by the cost of capture and the ability to
harvest the gas at scale. The technology to be deployed by SKH addresses
both issues, bringing the cost of capture comfortably below $100 per
metric ton at scale – the lowest in the industry – making it both
commercial and impactful towards reducing global warming.

SKH plans to deploy clusters of column shaped devices, or “mechanical
trees.” A cluster comprises 12 columns and can remove 1 metric ton of CO2
per day. SKH will deploy the technology in a pilot CO2 farm
targeting 100 metric tons per day of CO2. The technology will
then be deployed to full scale CO2 farms in multiple
locations, each capable of removing up to 3.8 million metric tons of CO₂
annually.

SKH holds the exclusive rights to the technology and comprises a group
of leading individuals from business and science, including Lackner.
Through the relationship with ASU, SKH will support ASU research and ASU
owns an interest in the shares of SKH.

Our goal is to accelerate the global climate effort set out in the
Paris Agreement to contribute to reversing global carbon emissions in
the next 10 to 15 years,” said Pól Ó Móráin, CEO of SKH. “Our passive
process is the evolution of carbon capture technology which has the
ability to be both economically and technologically viable at scale in a
reasonably short time frame,” added Ó Móráin.

The development of Klaus Lackner’s carbon capture device is but one
example of how ASU is developing novel technologies and business
opportunities to improve the environment and ensure a healthy Earth for
all well into the future,” said Peter Schlosser, vice president and vice
provost for Global Futures at ASU. “We are excited to be working with
SKH to bring this important technology for limiting global warming to
market.”

###

About Arizona State University
Arizona State University has
developed a new model for the American Research University, creating an
institution that is committed to access, excellence and impact. ASU
measures itself by those it includes, not by those it excludes. As the
prototype for a New American University, ASU pursues research that
contributes to the public good, and ASU assumes major responsibility for
the economic, social and cultural vitality of the communities that
surround it.

About Silicon Kingdom Holdings (SKH)
SKH holds the exclusive
worldwide rights to deploy carbon capture technology developed by
Professor Klaus Lackner, director of Arizona State University’s Center
for Negative Carbon Emissions. The proprietary technology acts like a
tree that is thousands of times more efficient at removing CO₂ from the
air. The “mechanical trees” allow the captured gas to be sequestered or
sold for re-use in a variety of applications, including synthetic fuels,
enhanced oil recovery or food, beverage and agriculture industries. The
technology offers passive, low-cost scalable capture of CO₂ from ambient
air. Deployed at scale, the technology can add meaningfully to other
global CO₂ initiatives to achieve significant reductions in the levels
of CO₂ in Earth’s atmosphere. SKH is based in Dublin, Ireland and
comprises a group of leading individuals from business and science,
including Professor Lackner.

Contacts

Arizona State University
Skip Derra
+1 480-965-4823

Silicon
Kingdom Holdings
Pól Ó Móráin, CEO
(via Vigo Communications)

Vigo
Communications
Ben Simons / Simon Woods
+44 (0)20-7390-0234
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Published

on

Continue Reading

Cannabis

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Published

on

Continue Reading

Innocan

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Published

on

innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial:-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey

HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.

As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.

“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”

“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”

For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+1 5162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania